B57.42 Meningoencephalitis in Chagas' disease

Name of the Condition

• Meningoencephalitis in Chagas' disease

Summary

Meningoencephalitis in Chagas' disease is a rare complication of the parasitic infection caused by Trypanosoma cruzi, involving inflammation of both the meninges and brain tissue. This condition can occur during the acute or chronic phases of Chagas' disease and affects the central nervous system. Transmission is primarily through contact with infected triatomine bug feces, though other routes like blood transfusion or congenital transmission are possible.

Causes

The infection is caused by Trypanosoma cruzi, a protozoan parasite. Meningoencephalitis develops when the parasite invades the meninges and brain, leading to inflammation. Transmission occurs when the parasite enters the body through breaks in the skin or mucous membranes, often via contact with infected triatomine bug feces. Other routes include blood transfusion, organ transplantation, congenital transmission from an infected mother, or ingestion of contaminated food or drink.

Risk Factors

• Residence in or travel to endemic regions (e.g., parts of Latin America).
• Exposure to triatomine bugs in rural or poorly constructed housing.
• Blood transfusion or organ transplantation from an infected donor.
• Congenital transmission from an infected mother.
• Lack of vector control measures in endemic areas.

Symptoms

• Severe headache.
• Fever.
• Stiff neck.
• Sensitivity to light (photophobia).
• Altered mental status or confusion.
• Seizures.
• Nausea or vomiting.
• Focal neurological deficits (e.g., weakness, numbness).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., MRI or CT scan to assess brain and meninges), and laboratory tests. Cerebrospinal fluid (CSF) analysis may show elevated white blood cells, protein, or parasites. Serological tests for Trypanosoma cruzi antibodies or PCR for parasite DNA can confirm the infection. A thorough history of exposure to endemic areas or risk factors is also critical.

Treatment Options

Treatment focuses on antiparasitic therapy (e.g., benznidazole or nifurtimox) to eliminate the parasite, along with supportive care for neurological symptoms. Corticosteroids may be used to reduce inflammation. Seizures or increased intracranial pressure may require anticonvulsants or other interventions. Management is often coordinated with infectious disease and neurology specialists.

Prognosis and Follow-Up

Prognosis depends on the severity of neurological involvement and timeliness of treatment. Early intervention improves outcomes, but severe cases may result in permanent neurological damage. Follow-up includes monitoring for symptom resolution, repeat imaging or CSF analysis if needed, and long-term assessment of neurological function. Chronic management may be required for persistent deficits.

Complications

• Permanent neurological damage (e.g., cognitive impairment, motor deficits).
• Seizure disorders.
• Increased intracranial pressure.
• Recurrent or chronic inflammation of the meninges or brain.
• Death in severe, untreated cases.

Lifestyle & Prevention

• Avoid exposure to triatomine bugs by using insect screens, bed nets, and insect repellent in endemic areas.
• Practice good hygiene and avoid consuming food or drink that may be contaminated with bug feces.
• Screen blood donors and organ recipients in endemic regions to prevent transfusion-related transmission.
• Pregnant individuals in endemic areas should undergo testing to prevent congenital transmission.

When to Seek Professional Help

Seek immediate medical attention if you experience severe headache, fever, stiff neck, confusion, seizures, or other neurological symptoms, especially if you have a history of Chagas' disease or exposure to endemic regions. Early evaluation is critical to prevent complications.

Tips for Medical Coders

Code B57.42 is specific to meningoencephalitis in Chagas' disease and should be used when both meningeal and brain inflammation are documented. Ensure the diagnosis aligns with clinical findings, including neurological symptoms and confirmation of Trypanosoma cruzi infection. Document the phase of Chagas' disease (acute or chronic) and any associated complications to support coding accuracy.